SUBJECTS : Immunology | Immunotherapy | Immune System | Therapeutic Vaccine
Immunotherapy Advances: 2022, vol: 2, issue: 1
- 1)- D Tatovic, M A McAteer, J Barry, A Barrientos, K Rodríguez Terradillos, I Perera, E Kochba, Y Levin, M Dul, S A Coulman, J C Birchall, C von Ruhland, A Howell, R Stenson, M Alhadj Ali, S D Luzio, G Dunseath, W Y Cheung, G Holland, K May, J R Ingram, M M U Chowdhury, F S Wong, R Casas, C Dayan, J Ludvigsson. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes. Immunotherapy advances. 2022, 2 (1): ltac002
Cited : 14Read More - 2)- Dayane Schmidt, Sima Ebrahimabadi, Kauan Ribeiro de Sena Gomes, Graziela de Moura Aguiar, Mariane Cariati Tirapelle, Renata Nacasaki Silvestre, Júlia Teixeira Cottas de Azevedo, Dimas Tadeu Covas, Virginia Picanço-Castro. Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy. Immunotherapy advances. 2022, 2 (1): ltac003Cited : 7Read More
- 3)- Simone Reinwald, Jennifer M Rolland, Robyn E O'Hehir, Menno C van Zelm. Peanut oral immunotherapy: current trends in clinical trials. Immunotherapy advances. 2022, 2 (1): ltac004Cited : 7Read More
- 4)- Guilherme Ferreira de Britto Evangelista, Amanda Braga Figueiredo, Milton José de Barros E Silva, Kenneth J Gollob. Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. Immunotherapy advances. 2022, 2 (1): ltac008Cited : 5Read More
- 5)- Mike Bogetofte Barnkob, Kristoffer Vitting-Seerup, Lars Rønn Olsen. Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy. Immunotherapy advances. 2022, 2 (1): ltac009Cited : 6Read More
- 6)- Beatriz Marton Freire, Filipe Menegatti de Melo, Alexandre S Basso. Adrenergic signaling regulation of macrophage function: do we understand it yet? Immunotherapy advances. 2022, 2 (1): ltac010Cited : 11Read More
- 7)- Tosca Holtrop, Kevin Budding, Arianne M Brandsma, Jeanette H W Leusen. Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer. Immunotherapy advances. 2022, 2 (1): ltac011Cited : 8Read More
- 8)- Josephine Zhang, Jesús A Siller-Farfán. Current and future perspectives of chimeric antigen receptors against glioblastoma. Immunotherapy advances. 2022, 2 (1): ltac014Cited : 2Read More
- 9)- Gabriel Pasquarelli-do-Nascimento, Sabrina Azevedo Machado, Juliana Maria Andrade de Carvalho, Kelly Grace Magalhães. Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. Immunotherapy advances. 2022, 2 (1): ltac015Cited : 5Read More
- 10)- Abdulhadi Jfri, Bonnie Leung, Jordan T Said, Yevgeniy Semenov, Nicole R LeBoeuf. Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors. Immunotherapy advances. 2022, 2 (1): ltac016Cited : 6Read More
- 11)- Liam V Brown, Jonathan Wagg, Rachel Darley, Andy van Hateren, Tim Elliott, Eamonn A Gaffney, Mark C Coles. De-risking clinical trial failure through mechanistic simulation. Immunotherapy advances. 2022, 2 (1): ltac017Cited : 2Read More
- 12)- . Correction. Immunotherapy advances. 2022, 2 (1): ltac018Cited : 0Read More
- 13)- Stephanie Schwartz, Nidhi Patel, Tyler Longmire, Pushpa Jayaraman, Xiaomo Jiang, Hongbo Lu, Lisa Baker, Janelle Velez, Radha Ramesh, Anne-Sophie Wavreille, Melanie Verneret, Hong Fan, Tiancen Hu, Fangmin Xu, John Taraszka, Marc Pelletier, Joy Miyashiro, Mikael Rinne, Glenn Dranoff, Catherine Sabatos-Peyton, Viviana Cremasco. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunotherapy advances. 2022, 2 (1): ltac019Cited : 20Read More
- 14)- Gavin R Meehan, Hannah E Scales, Iain B McInnes, James M Brewer, Paul Garside. Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration. Immunotherapy advances. 2022, 2 (1): ltac020Cited : 1Read More
- 15)- Stefan Barth, Krupa Naran. TIM-3: a tumor-associated antigen beyond checkpoint inhibition? Immunotherapy advances. 2022, 2 (1): ltac021Cited : 0Read More
- 16)- Rifat S Rahman, Duane R Wesemann. Immunology of allergen immunotherapy. Immunotherapy advances. 2022, 2 (1): ltac022Cited : 0Read More
